These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9202817)

  • 41. Two booster dose hepatitis B virus vaccination in patients with leukemia.
    Yetgin S; Tunç B; Koç A; Toksoy HB; Ceyhan M; Kanra G
    Leuk Res; 2001 Aug; 25(8):647-9. PubMed ID: 11397468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients.
    Lefebure AF; Verpooten GA; Couttenye MM; De Broe ME
    Vaccine; 1993; 11(4):397-9. PubMed ID: 8470423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates.
    Gunn TR; Bosley A; Woodfield DG
    N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preclinical evaluation of a two-dose vaccination schedule of recombinant Hansenula polymorpha hepatitis B vaccine in animals.
    Li J; Zhang D; Ma R; Yang X; Wang X; Li C; Zhang S; Xue H; Zhao K; Zhuang H
    Hum Vaccin Immunother; 2013 Apr; 9(4):736-43. PubMed ID: 23370192
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Studies on the status of immune memory after completion of hepatitis B vaccination].
    Li YP; Li RC; Fang KX; Li HM; Hu ZY; He P; Wu XY; Zhang R; Liang ZL; Zhuang H
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Apr; 28(4):319-21. PubMed ID: 17850693
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.
    Zanetti AR; Mariano A; Romanò L; D'Amelio R; Chironna M; Coppola RC; Cuccia M; Mangione R; Marrone F; Negrone FS; Parlato A; Zamparo E; Zotti C; Stroffolini T; Mele A;
    Lancet; 2005 Oct 15-21; 366(9494):1379-84. PubMed ID: 16226616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Effect analysis on non-and-low response infants after revaccinated hepatitis B vaccine].
    Wu ZH; Cui FQ; Gong XH
    Zhongguo Yi Miao He Mian Yi; 2010 Jun; 16(3):207-10. PubMed ID: 20726258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.
    Levie K; Gjorup I; Skinhøj P; Stoffel M
    Scand J Infect Dis; 2002; 34(8):610-4. PubMed ID: 12238579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago.
    Wang LY; Lin HH
    Vaccine; 2007 Oct; 25(41):7160-7. PubMed ID: 17707557
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Duration of protection after infant hepatitis B vaccination series.
    Middleman AB; Baker CJ; Kozinetz CA; Kamili S; Nguyen C; Hu DJ; Spradling PR
    Pediatrics; 2014 Jun; 133(6):e1500-7. PubMed ID: 24843060
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistence of antibody to hepatitis B surface antigen after low-dose, intradermal hepatitis B immunization and response to a booster dose.
    Bryan JP; Sjogren MH; Macarthy P; Cox E; Legters LJ; Perine PL
    Vaccine; 1992; 10(1):33-8. PubMed ID: 1531719
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-HBs levels in infants of hepatitis B carrier mothers after delayed active immunization with recombinant vaccine concomitant with DTP-polio vaccine: is there need for a second dose of HBIg? Dutch Study Group on Prevention of Neonatal Hepatitis B.
    Grosheide PM; del Canho R; Voogd M; Heijtink RA; Schalm SW
    Vaccine; 1994 Sep; 12(12):1059-63. PubMed ID: 7998413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunogenicity and safety of recombinant yeast-derived hepatitis B vaccine in haemodialysis patients.
    Fujiyama S; Yoshida K; Sato T; Shimada H; Deguchi T
    Hepatogastroenterology; 1990 Dec; 37 Suppl 2():140-4. PubMed ID: 2150664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and reactogenicity of two recombinant hepatitis B vaccines in small infants: a randomized, double-blind comparative study.
    Sapru A; Kulkarni PS; Bhave S; Bavdekar A; Naik SS; Pandit AN
    J Trop Pediatr; 2007 Oct; 53(5):303-7. PubMed ID: 17478542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Persistence of HB vaccine immune protection and response to hepatitis B booster immunization].
    Li H; Li R; Liao S; Yang J; Zeng X
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Feb; 20(1):54-9. PubMed ID: 11367735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine.
    Zhang W; Han L; Lin C; Wang H; Pang X; Li L; Gao P; Lin H; Gong X; Tang Y; Ma J; Zhang H; Wang C; Yang P; Li H; Sun M; He X
    Vaccine; 2011 Aug; 29(37):6276-82. PubMed ID: 21722684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis B vaccination in children with cancer.
    Berberoğlu S; Büyükpamukcu M; Sarialioglu F; Akyüz C; Ilhan I
    Pediatr Hematol Oncol; 1995; 12(2):171-8. PubMed ID: 7626386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Humoral immune response following hepatitis B vaccine booster dose in children with and without prior immunization.
    Chongsrisawat V; Theamboonlers A; Khwanjaipanich S; Owatanapanich S; Sinlaparatsamee S; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):623-6. PubMed ID: 11414401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothers.
    Belloni C; Orsolini P; Martinetti M; Chirico G; Cerbo RM; Comolli G; Maccarini U; Barlassina C; Togni C; Polatti F
    New Microbiol; 1993 Jul; 16(3):237-44. PubMed ID: 8366819
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparative study of the immunogenicity and safety of Engerix-B administered at 0, 1, 2 and 12 months and Recombivax HB administered at 0, 1, and 6 months in healthy adults.
    Rustgi VK; Schleupner CJ; Krause DS
    Vaccine; 1995 Dec; 13(17):1665-8. PubMed ID: 8719517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.